Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, will showcase its portfolio of cutting edge innovative technologies at the 2013 Boston AF meeting. Boston AF, now in its 18
year, provides a scientific forum for health care professionals to learn about advances in research and therapeutics in the field of atrial fibrillation.
At the meeting, Biosense Webster will showcase its complete portfolio of market-leading technologies and present an array of innovative solutions for Electrophysiologists and Allied Health Professionals including:– Clinical Support, Global Education and Training Programs, Technical Service, Patient Education, and other resources to support the expanded access to ablation treatment.
The new CARTOALARA
Module for the company’s CARTO
3 System will be introduced at Boston AF. The CARTOALARA
Module seamlessly combines a fluoroscopy image and CARTO
3 System maps into a single view and helps lower fluoroscopy levels to as low as reasonably achievable. Complementing the accuracy of the CARTO
System proprietary magnetic navigation technology, the CARTOALARA
Module is an open architecture technology designed to work with a variety of industry leading fluoroscopy systems allowing customers to convert many of their legacy systems with minimal effort.
“This new advance allows electrophysiologists to navigate with confidence from one integrated view,” said Shlomi Nachman, Worldwide President, Biosense Webster. “The safety of our physician customers and their patients is very important to us and we are leading an industry-wide initiative with the goal of dramatically reducing fluoroscopy use in the EP lab without compromising safety.”
Combined with the CARTO
System Advanced Catheter Location (ACL) Technology, Fast Anatomical Mapping (FAM) capability and its CONNECTION OF CHOICE
functionality, the CARTOALARA
Module adds a new dimension to the CARTO® System’s established electroanatomical mapping accuracy, reinforcing user trust and confidence.
Module will be commercially available in the United States and Europe starting in February 2013.
About AF and cardiac ablation
Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only ~130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life.